EP1450816A4 - Method of treating disorder related to high cholesterol concentration - Google Patents
Method of treating disorder related to high cholesterol concentrationInfo
- Publication number
- EP1450816A4 EP1450816A4 EP02802882A EP02802882A EP1450816A4 EP 1450816 A4 EP1450816 A4 EP 1450816A4 EP 02802882 A EP02802882 A EP 02802882A EP 02802882 A EP02802882 A EP 02802882A EP 1450816 A4 EP1450816 A4 EP 1450816A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- high cholesterol
- cholesterol concentration
- disorder related
- treating disorder
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34802001P | 2001-11-08 | 2001-11-08 | |
US348020P | 2001-11-08 | ||
PCT/US2002/035900 WO2003039480A2 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1450816A2 EP1450816A2 (en) | 2004-09-01 |
EP1450816A4 true EP1450816A4 (en) | 2008-02-13 |
Family
ID=23366328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02802882A Withdrawn EP1450816A4 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1450816A4 (en) |
JP (1) | JP2005508368A (en) |
CA (1) | CA2466033A1 (en) |
TW (1) | TW200300078A (en) |
WO (1) | WO2003039480A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078396B2 (en) | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
EP1806332A4 (en) | 2004-10-27 | 2010-03-31 | Daiichi Sankyo Co Ltd | Benzene compound having 2 or more substituents |
US8129358B2 (en) | 2006-11-13 | 2012-03-06 | Novartis Ag | Substituted pyrazole and triazole compounds as KSP inhibitors |
US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
LT2753632T (en) * | 2011-09-08 | 2023-07-10 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US20160022701A1 (en) * | 2013-03-13 | 2016-01-28 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
ES2699445T3 (en) | 2013-03-13 | 2019-02-11 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
JP2016193835A (en) * | 2013-09-04 | 2016-11-17 | 学校法人常翔学園 | Nuclear receptor liver X receptor agonist |
EA201990684A1 (en) | 2013-12-24 | 2020-12-30 | Вирджиния Коммонвелт Юниверсити | METHODS OF APPLICATION OF OXYGENATED CHOLESTEROL SULPHATES (OCS) |
US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
CA2991311A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
MX2020010690A (en) | 2015-07-06 | 2022-02-25 | Sage Therapeutics Inc | Oxysterols and methods of use thereof. |
IL256710B2 (en) | 2015-07-06 | 2024-01-01 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
PL3436022T3 (en) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
SI3481846T1 (en) | 2016-07-07 | 2021-11-30 | Sage Therapeutics, Inc. | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions |
MX2019001323A (en) | 2016-08-02 | 2019-07-04 | Univ Virginia Commonwealth | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide. |
ES2935057T3 (en) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 substituted oxysterols and these compounds for use as NMDA modulators |
RU2019115112A (en) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | OXYSTEROLES AND METHODS OF THEIR APPLICATION |
CA3234484A1 (en) | 2016-10-18 | 2018-04-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1405818A (en) * | 1972-12-06 | 1975-09-10 | Shionogi & Co | 6beta-amino-steroids and the preparation thereof |
WO1994002503A1 (en) * | 1992-07-22 | 1994-02-03 | Enosys S.A. | Bile acid derivative and use thereof in therapy |
WO2000066611A1 (en) * | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
WO2002090375A2 (en) * | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963765A (en) * | 1973-04-01 | 1976-06-15 | Yehuda Mazur | Preparation of derivatives of cholesterol |
US4217288A (en) * | 1977-03-24 | 1980-08-12 | Wisconsin Alumni Research Foundation | Anti-vitamin D compounds |
JPS61254599A (en) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | Fluorine derivative of cholesterol |
IL105050A0 (en) * | 1992-03-27 | 1993-07-08 | Lilly Co Eli | Steroid derivatives |
-
2002
- 2002-11-08 TW TW091132850A patent/TW200300078A/en unknown
- 2002-11-08 JP JP2003541772A patent/JP2005508368A/en active Pending
- 2002-11-08 CA CA002466033A patent/CA2466033A1/en not_active Abandoned
- 2002-11-08 WO PCT/US2002/035900 patent/WO2003039480A2/en active Application Filing
- 2002-11-08 EP EP02802882A patent/EP1450816A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1405818A (en) * | 1972-12-06 | 1975-09-10 | Shionogi & Co | 6beta-amino-steroids and the preparation thereof |
WO1994002503A1 (en) * | 1992-07-22 | 1994-02-03 | Enosys S.A. | Bile acid derivative and use thereof in therapy |
WO2000066611A1 (en) * | 1999-04-30 | 2000-11-09 | Arch Development Corporation | Steroid derivatives |
WO2002090375A2 (en) * | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
Non-Patent Citations (5)
Title |
---|
LAFFITTE B A ET AL: "LXRS CONTROL LIPID-INDUCIBLE EXPRESSION OF THE APOLIPOPROTEIN E GENE IN MACROPHAGES AND ADIPOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 2, 16 January 2001 (2001-01-16), pages 507 - 512, XP001097136, ISSN: 0027-8424 * |
SONG C ET AL: "EFFECTS OF SELECTIVE LIVER X RECEPTOR AGONIST ON ATHEROSCLEROSIS PROGRESSION AND REGRESSION OF APOE KNOCK-OUT MICE", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 104, no. 17, 23 October 2001 (2001-10-23), pages II329, XP009016063, ISSN: 0009-7322 * |
SONG C ET AL: "Hypolipidemic effects of selective liver X receptor alpha agonists", STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 66, no. 9, September 2001 (2001-09-01), pages 673 - 681, XP004304415, ISSN: 0039-128X * |
SONG C ET AL: "SELECTIVE ACTIVATION OF LIVER X RECEPTOR ALPHA BY 6ALPHA-HYDROXY BILE ACIDS AND ANALOGS", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 65, no. 8, 2000, pages 423 - 427, XP000952749, ISSN: 0039-128X * |
SPARKS D L ET AL: "Link between heart disease, cholesterol, and Alzheimer's disease: a review.", MICROSCOPY RESEARCH AND TECHNIQUE 15 AUG 2000, vol. 50, no. 4, 15 August 2000 (2000-08-15), pages 287 - 290, XP002462914, ISSN: 1059-910X * |
Also Published As
Publication number | Publication date |
---|---|
WO2003039480A2 (en) | 2003-05-15 |
WO2003039480A3 (en) | 2003-06-19 |
TW200300078A (en) | 2003-05-16 |
JP2005508368A (en) | 2005-03-31 |
CA2466033A1 (en) | 2003-05-15 |
EP1450816A2 (en) | 2004-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1450816A4 (en) | Method of treating disorder related to high cholesterol concentration | |
GB0014969D0 (en) | Novel method of treatment | |
AU2003283958A8 (en) | Method of treating tremors | |
EP1405933A4 (en) | Treating solution for surface treatment of metal and surface treatment method | |
AU2003226301A8 (en) | Method of treating cancer | |
EP1393708A4 (en) | Method of treating hair | |
AU2003256847A8 (en) | Method of treating cancer | |
EP1677794A4 (en) | Methods of treating disorder | |
ZA200409331B (en) | Method of treating diabetes | |
IL158439A0 (en) | Method of treating atmospheric pollutants | |
AU2002365814A8 (en) | Method of treating asthma | |
EP1282411A4 (en) | Method of treating cancer | |
EP1389105A4 (en) | Method of treatment | |
GB0112216D0 (en) | Method of treatment | |
GB2368397B (en) | Method of treating biological specimens | |
GB2369675B (en) | Method of treating biological specimens | |
GB0118892D0 (en) | Method of treatment | |
GB2370115B (en) | Method of treating biological specimens | |
GB2370635B (en) | Method of treating biological specimens | |
GB0008921D0 (en) | Method of treatment | |
EP1389129A4 (en) | Methods of treating respiratory conditions | |
GB2381312B (en) | Methods relating to treatment of atherosclerosis | |
EP1604748A4 (en) | Method of treating waste glass | |
EP1423118A4 (en) | Method and composition for treatment of cancer | |
IL161630A0 (en) | Methods of treating endometreosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040604 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SONG, CHING Inventor name: LIAO, SHUTSUNG |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20071219BHEP Ipc: A61P 9/10 20060101ALI20071219BHEP Ipc: A61P 3/06 20060101ALI20071219BHEP Ipc: A61K 31/575 20060101AFI20071219BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080114 |
|
17Q | First examination report despatched |
Effective date: 20090206 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090818 |